SCOTS sufferers of a rare form of cystic fibrosis have finally been given access to a revolutionary new drug that could extend their life expectancy by 18 years.
Campaigners have been calling for Kalydeco, also known as Ivacaftor, to made available in Scotland, but the drug was rejected for use on the NHS due to cost – despite it being available in England.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
